The Food and Drug Administration (FDA) has approved Isturisa ® (osilodrostat) for the treatment of endogenous hypercortisolemia in adults with Cushing syndrome for whom surgery is not an option or has ...

Osilodrostat, an oral cortisol synthesis inhibitor, was previously approved for treating adults with Cushing disease, a subtype of Cushing syndrome in which the hypercortisolemia is due to pituitary ...

Previously, the treatment had been indicated for Cushing disease, a subtype of Cushing syndrome. Isturisa is a cortisol synthesis inhibitor. By blocking 11-beta-hydroxylase, the enzyme responsible ...

Corcept sees 40% growth in 2025 revenue with promising trials, expanded patient base, and strong projections. Read my ...

Cushing’s syndrome survivor and public health advocate ... Fari called on President Bola Ahmed Tinubu’s administration to invest in rare disease research, strengthen advocacy, and train ...

Italian pharma major Recordati (RECI: MI) today announced that the US Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Isturisa (osilodrostat) for the ...

Novo Nordisk submitted an oral version of the weight-loss formulation of semaglutide (Wegovy) for FDA approval, according to ...

The treatment strategy for congenital adrenal hyperplasia is burdensome and had not changed in more than 70 years until the ...